RxDoctor Payments Data

Mary Beth Wiles, MD

Internal Medicine · Blairsville, GANPI 1407863285

Payments from drug & device makers

$7,014in general payments, 2019–2025

Across 333 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$991
  • Amgen$600
  • Pfizer$399
  • Bayer$397
  • Lilly USA, LLC$373
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,25189%
  • Other$76311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,014 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$565,333
Medicare patients
696
Services billed
9,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$108,225
EliquisApixaban66$78,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$40,025
JardianceEmpagliflozin26$38,342
Repatha SureclickEvolocumab31$37,242
GemtesaVibegron44$36,259
OzempicSemaglutide25$36,249
FarxigaDapagliflozin Propanediol26$31,586
ArexvyRsvpref3 Antigen/As01e/Pf103$31,481
MounjaroTirzepatide22$28,284
LinzessLinaclotide16$20,699
MyrbetriqMirabegron15$16,492
XareltoRivaroxaban13$14,618
ShingrixVaricella-Zoster Ge/As01b/Pf63$13,877
Repatha PushtronexEvolocumab12$11,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Shingrix$285$85,384201 claims
PfizerEliquis, Premarin$399$84,62777 claims
Boehringer IngelheimJardiance$215$38,34226 claims
Sumitomo Pharma America, Inc.Gemtesa$177$36,25944 claims
Novo NordiskOzempic$1,002$36,24925 claims
AstraZenecaFarxiga$244$31,58626 claims
Lilly USA, LLCMounjaro$373$28,28422 claims
AbbVieLinzess, Synthroid$356$24,77862 claims
Astellas Pharma US IncMyrbetriq$41$16,49215 claims
Johnson & JohnsonXarelto$27$14,61813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Blairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →